Transgene - Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR

Invir.IO® based oncolytic virus TG6050, is armed with IL-12 and an anti-CTLA4 antibody. A Phase I trial (Delivir) recently started enrolling patients with advanced non-small cell lung cancer (NSCLC)

Related Keywords

United States ,Copenhagen ,Køavn ,Denmark ,American ,Transgene Euronext ,Lucie Larguier ,Ben Brahim ,Astrazeneca ,Corporate Communications ,Twitter ,American Association For Cancer Research ,Euronext Paris ,American Association ,Cancer Research ,Annual Meeting ,Phasei Delivir ,Artificial Intelligence ,Risk Factors ,Universal Registration Document ,Transgene ,Reclinical ,Results ,Showing ,G6050 ,Novel ,Ncolytic ,Virus ,Induces ,Humor ,Regression ,Deactivating ,Yinnate ,Adaptive ,Immune ,Responses ,Resented ,Racr ,